跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
Approvals
/
TGA
/
POTELIGEO mogamulizumab 4 mg/mL concentrate for solution for infusion vial
Approved
STANDARD
POTELIGEO mogamulizumab 4 mg/mL concentrate for solution for infusion vial
Kyowa Kirin Australia Pty Ltd
🇦🇺 Therapeutic Goods Administration
Approval Date
May 30, 2025
Approval ID
a980e3638e1bc1d3
Company
Kyowa Kirin Australia Pty Ltd
Type
Standard
Approval Details
Approval Id
a980e3638e1bc1d3
Product Name
POTELIGEO mogamulizumab 4 mg/mL concentrate for solution for infusion vial
Artg Id
330232
Artg Name
POTELIGEO mogamulizumab 4 mg/mL concentrate for solution for infusion
Sponsor
Kyowa Kirin Australia Pty Ltd
Company Detail Path
/organization/kyowa-kirin-australia-pty-ltd
Artg Date
2021-02-05
Registration Type
Medicine
Therapeutic Good Type
Medicine
Licence Status
A
Licence Category
RE
Consumer Medicine Info
https://medical-cdn.nocode.com/drug_tga/94bd0bcf11fc272162a0f679ba0c276c.pdf
Product Information
https://medical-cdn.nocode.com/drug_tga/a7a2ce1b000b96bf265642857541ec98.pdf
Active Ingredients
Approved
Quick Info
Agency
TGA
Country
🇦🇺
Approval Date
May 30, 2025
Approval ID
a980e3638e1bc1d3
Type
Standard
Back to TGA Approvals
POTELIGEO mogamulizumab 4 mg/mL concentrate for solution for infusion vial - TGA Drug Approval Details
